NK cells participate in host protection by eliminating cells with altered expression of self -MHC class I (MHC-I), which can result from viral infection or transformation ( 1 ) . Although we are beginning to appreciate a role for viral and stress-induced ligands in NK cell activation, the best described regulatory mechanism of NK cell activity is the expression of inhibitory receptors for self -MHC-I ligands by mature NK cells with high cytotoxic potential. In man, killer Ig-like receptors (KIRs) recognizing the classical MHC-I molecules HLA-A, -B, or -C are expressed on the predominate peripheral NK cell (CD56 lo CD16 + ) subset, which possesses abundant intracellular perforin and granzymes and displays spontaneous cytotoxicity ( 1 ) . In contrast, CD-56 hi CD16 Ϫ NK cells rarely express KIRs, and because they are more prevalent in blood early after bone marrow transplant ( 2, 3 ) , give rise to CD56 lo CD16 + NK cells when transferred into NOD/SCID mice ( 4 ) , and have longer telomeres than CD56 lo CD16 + NK cells ( 5 ) , it is likely that CD56 hi CD16 Ϫ NK cells are (or contain within this population) precursors of CD56 lo CD16 + NK cells; however, the tools to defi nitively prove this hypothesis are lacking. 
The in vivo requirements for human natural killer (NK) cell development and differentiation into cytotoxic effectors expressing inhibitory receptors for self -major histocompatability complex class I (MHC-I; killer Ig-like receptors [KIRs

RESULTS AND DISCUSSION Human hematopoietic chimerism and NK cell development in HIS mice
Human HSCs engrafted into newborn BALB/c Rag2 Ϫ / Ϫ ␥ c Ϫ / Ϫ mice develop into mature myeloid and lymphoid cells ( 15, 16 ) . We used this approach to investigate human NK cell development in vivo . 8 -12 wk after HSC engraftment, HIS mice displayed human hematopoietic chimerism in all organs analyzed, with human thymopoiesis, B lymphopoiesis, and myelopoiesis evident ( Fig. 1, A Using an NK cell -specifi c antibody (anti-NKp46), we identifi ed human NK cells in all lymphoid organs of HIS mice, although at low frequencies, typically between 0.3 and 1.5% of human lymphocytes ( Fig. 1 A ) . Both CD56 hi CD16 Ϫ and CD56 lo CD16 + NK cells subsets are present, with the majority of NK cells having the latter phenotype ( Fig. 1 C ) . Interestingly, some CD16 + cells expressed CD56 at levels indistinguishable from non -NK cells. These CD56 lo cells are NK cells, as they express NKp46, NKG2D, CD94, and, like their counterparts in man, KIRs, whereas CD56 hi CD16 Ϫ cells are rarely KIRs + ( Fig. 1 C ) . NKp46 + cells present a phenotype consistent with peripheral NK cells in man including expression of CD122 (IL-2R ␤ ), NKG2A, CD161, but not CD3 ( Fig. 1 D ) . In vivo -generated human NK cells express high levels of intracellular granzyme B and IFN-␥ when stimulated with IL-12 and -18 ex vivo, and they degranulate when co-cultured with K562 human leukemia cells as determined by expression of CD107a ( Fig. 1 E ) .
IL-15 is a pleiotropic cytokine essential for mouse NK cell development ( 10 ) . Given the sparse number of human NK cells, we hypothesized that IL-15 availability in this HIS model might be suboptimal. HIS mice represent a hybrid human -mouse system where cytokine receptor compatibility between species may not exist. Specifi cally, although human IL-15 (hIL-15) induces survival and proliferation of mouse NK cells ( 17, 18 ) , it is not clear whether the reverse is true. This is a critical question, as we expect most of the IL-15 in HIS mice to be mouse-derived given the low human myeloid ( 15 ) or absent epithelial/stromal cell chimerism (cells likely to be sources of IL-15) ( 10, 19 ) . We found that human NK cells cultured in vitro with hIL-15 proliferated extensively (predominately the CD56 hi CD16 Ϫ subset); this was in contrast to those cultured in mouse IL-15 (mIL-15), which itself suffi ciently induced proliferation of mouse NK cells ( Fig. 1 F and Fig. S2 , available at http://www.jem.org/cgi/ content/full/jem.20082013/DC1). Given that mIL-15 is trans-presented in vivo, we investigated the eff ect of culturing human NK cells with low concentrations of IL-15 alone or IL-15 trans-presented by IL-15R ␣ -Fc of the same or alternate species. Irrespective of which species of IL-15R ␣ was used, mIL-15 failed to induce human NK cell proliferation, although some cells survived when mIL-15 was combined with hIL-15R ␣ -Fc ( Fig. 1 G ) . In contrast, hIL-15R ␣ was clearly superior in inducing NK cell proliferation compared with mIL-15R ␣ when combined with hIL-15 ( Fig. 1 G ) .
Although inhibitory KIRs control reactivity of mature NK cells, their expression also infl uences the functional maturation of developing NK cells, as NK cells expressing at least one KIR-recognizing self -MHC-I have a lower threshold of activation and appear more functional than NK cells expressing no KIRs or those only expressing KIRs recognizing nonself -MHC-I ligands ( 6 ) . In addition, patients lacking the transporter associated with antigen processing have dramatically reduced MHC-I surface expression and, consequently, hyporesponsive NK cells to MHC-I -defi cient cells ( 7 ) . KIR + NK cells are present in these patients, indicating that normal MHC-I expression itself is not required for KIR expression ( 7 ) . This phenomenon termed " licensing " or " disarming " has been better characterized in mice, and suggests a role for KIR -self -MHC-I interactions during human NK cell development. Given the importance of KIR expression in regulating NK cell function, knowledge of elements infl uencing KIR acquisition would improve our understanding and clinical approaches to diseases where KIR and HLA haplotypes infl uence susceptibility, progression, or outcome of autoimmune/infl ammatory disease, cancer, hematopoietic grafts, and infections ( 8 ) .
Because KIRs are expressed on mature CD56 lo CD16 + NK cells, factors that infl uence NK cell homeostasis could potentially infl uence KIR acquisition in vivo. An elegant series of mouse studies using gene targeting and bone marrow chimeras have revealed that NK cell development requires IL-15R ␣ -expressing cells to chaperone IL-15 to the surface, where it is bioactive and signifi cantly more potent in inducing activation and proliferation of IL-15R ␤ ␥ -expressing cells via trans-presentation ( 9, 10 ) . When not bound to IL-15R ␣ , IL-15 appears to have a minimal eff ect on NK cell homeostasis in vivo ( 11, 12 ) . In humans, mutations in IL-15R ␣ have not been reported; however, NK cells are dramatically reduced in patients carrying mutations in the common ␥ chain ( ␥ c) cytokine receptor (used in IL-15, -7, -4, -9, -2, and -21 signal transduction), Jak3, or the shared IL-2/-15R ␤ , whereas they are present in IL-7R ␣ -defi cient patients, suggesting that IL-15 may regulate human NK cell development ( 13, 14 ) .
In vivo studies of NK cells have been largely restricted to mice, and although this line of experimentation is valuable, some of this knowledge is not transferable to human NK cell biology. A clear example of this is NK cell development, where the kinetics, frequency, and phenotype are clearly different between species ( 1 ) . An intermediate between mouse and human in vivo studies exists in the form of human immune system (HIS) mice. A recently developed HIS mouse model is the engraftment of newborn BALB/c Rag2 Ϫ / Ϫ ␥ c Ϫ / Ϫ mice with human hematopoietic stem cells (HSCs) from fetal liver or cord blood ( 15, 16 ) . BALB/c Rag2 Ϫ / Ϫ ␥ c Ϫ / Ϫ HIS mice represent a practical HIS model with high human chimerism, most lymphocyte lineages generated, and adaptive immune responses occasionally evoked ( 15, 16 ) .
In this study, using HIS BALB/c Rag2 Ϫ / Ϫ ␥ c Ϫ / Ϫ mice engrafted with fetal liver HSCs, we study the in vivo role of IL-15 trans-presentation in human NK cell homeostasis. Similarly, activated human, but not mouse, myeloid cells were able to induce human NK cell proliferation in vitro ( Fig. S2 ). Last, human NK cells are observed in athymic HIS mice (Rag2 Ϫ / Ϫ ␥ c Ϫ / Ϫ FOXN1 Ϫ / Ϫ ), ruling out a major role for T cell -derived IL-2 driving NK cell development ( Fig. 1 H ) .
BRIEF DEFINITIVE REPORT
Collectively, these data indicate that the few resident NK cells in HIS mice are dependent on the available hIL-15. Indeed, the number of human NK cells in the spleen of HIS mice could be further reduced after treatment with neutralizing antibody against human, but not mouse, IL-15 ( Fig. S2 ). Furthermore, hIL-15R ␣ + cells known to express IL-15 and support NK cell development, such as members of the myeloid lineage, are found in the bone marrow of HIS mice (unpublished data) ( 10, 15 ) . Given this last point, it is possible that enhancing the chimerism of hIL-15/-15R ␣ -expressing cells will improve human NK cell development in HIS mice.
Given the likely dependence of human NK cells on hIL-15, we next treated HIS mice with the same concentration of hIL-15 alone or hIL-15 preincubated with hIL-15R ␣ -Fc to mimic IL-15 trans-presentation in vivo. Consistent with mouse studies ( 11, 12 ) , we observed a signifi cant increase in NK cell frequency when hIL-15 was complexed to IL-15R ␣ -Fc, but not when administered alone ( Fig. 2 A ) . Increased NK lymphopoiesis by hIL-15+IL-15R ␣ -Fc compared with IL-15 alone was associated with increased Bcl-xL expression and cell proliferation, as demonstrated by BrdU uptake and Ki-67 expression ( Fig. 2 B ) . These data indicate that IL-15R -mediated human NK cells responses are more readily evoked in vivo when IL-15 is complexed to IL-15R ␣ -Fc.
We next compared two diff erent IL-15R agonists, both mimicking IL-15 trans-presentation, hIL-15+IL-15R ␣ -Fc, and RLI (hIL-15 covalently linked to an hIL-15R ␣ extended sushi domain, but lacking any Fc fragment) ( 11, 12, 20 ) . Four injections of 2.5 μ g hIL-15R agonists (one per week) resulted in a signifi cant increase in the number of NKp46 + cells in all organs ( Fig. 2 C ) . Both these agonists markedly enhanced NK cell in vivo uptake of BrdU; expression of Bcl-xL, Ki-67, and CD69; and resulted in delayed apoptosis of NK cells when withdrawn from cytokines ( Fig. 2, D and E , and not depicted), suggesting both proliferation and survival result from IL-15+IL-15R ␣ binding to NK cells in vivo. Human CD8 T cells were also signifi cantly augmented in HIS mice and had an obvious increase in BrdU uptake after treatment with RLI ( Fig. 2 F ) . Interestingly, RLI that activates both the IL-15R ␤ / ␥ and IL-15R ␣ / ␤ / ␥ was consistently more eff ective in vivo than noncovalent association of hIL-15+hIL-15R ␣ -Fc that activates IL-15R ␤ / ␥ alone. This observation is in agree-ment with in vitro studies showing RLI functions more efficiently than the noncovalent associations of IL-15 + sushi domain or other soluble forms of IL-15R ( 20, 21 ) . The evident eff ect of RLI compared with IL-15+IL-15R ␣ -Fc also indicates that the Fc protein does not contribute to the augmented NK lymphopoiesis and rules out any activation of human NK cells through CD16.
Although IL-15 is known to heighten NK cell cytotoxicity and induce proliferation, it also protects cells from apoptosis (the latter possible at lower concentrations) by suppressing proapoptotic Bim and elevating Bcl-2 family members such as Bcl-xL and Mcl-1 ( 18, 22, 23 ) . A clear in vivo eff ect of RLI and IL-15+IL-15R ␣ -Fc was the up-regulation of Bcl-xL in NK cells ( Fig. 2, B and E ). We next asked if enhanced survival could improve NK cell reconstitution in the limiting hIL-15 environment of HIS mice. To address this, HSCs were infected with a bicistronic retrovirus encoding the prosurvival protein Bcl-xL and GFP (to detect infected cells) in vitro before engrafting newborn BALB/c Rag2 Ϫ / Ϫ ␥ c Ϫ / Ϫ mice. Ectopic expression of Bcl-xL in human HSCs resulted in a signifi cant increase in thymocyte and splenocyte cellularity 8 wk after engraftment, with Bcl-xL -transduced cells (GFP + ) representing a greater proportion of hCD45 + cells compared with control transduced cells in all organs ( Fig. 3 , A -C ). NKp46 + cells were signifi cantly increased in thymus and spleen of Bcl-xL HIS mice compared with control HIS mice; however, this appeared to be primarily a result of increased cellularity in these organs as the percentage of NK cells largely unchanged ( Fig. 3, D and E ) . In addition, although a greater proportion of NK cells were GFP + in Bcl-xL -infected mice compared with controls, no accumulation of Bcl-xL -expressing NK cells was observed among the most mature subset (CD56 lo CD16 + ). Lastly, the number of NK cells in HIS mice engrafted with Bcl-xL -infected HSCs, in terms of absolute numbers and fold diff erence compared with control, were substantially lower than mice treated with transpresented IL-15. These fi ndings indicate that IL-15/IL-15R ␣ eff ects extend beyond providing survival signals in promoting human NK cell development in vivo.
A consistent observation in all lymphoid organs after treatment with trans-presented IL-15 was the skewing of NK cell maturation toward the more diff erentiated CD56 lo CD16 + phenotype. In particular, we observed signifi cant and specifi c increases in the frequency of CD16 + NK cells and the ratio of CD16 + /CD16 Ϫ NK cells 7 d after the fi nal treatment ( Fig. 4,  A and B ). This in vivo accumulation is consistent with a model where CD56 lo CD16 + NK cells represents the terminal stage of highest in the thymus and elevated compared with normal frequencies in human blood (typically 50 -60%). This may result from greater IL-15 concentrations in our model compared with humans; however, the frequency of KIR + NK cells in human thymus has not been reported using all existing commercial antibodies to KIRs. In contrast to IL-15 trans-presentation, no enhanced NK cell diff erentiation and induction of KIR expression was observed in HIS mice treated with IL-15 alone or in those engrafted with Bcl-xL -expressing HSCs ( Fig. 4 C ) . Furthermore, the increase in KIR + NK cells did not represent an expansion of one CD56 lo CD16 + KIR + NK clone, as CD-56 lo CD16 + NK cells expressing a combination of 1 -5 diff erent KIR members were present in this population ( Fig. 4 D ) .
It is unlikely the accumulation of CD56 lo CD16 + NK cells results from a preferential expansion of this subset in response to hIL-15 trans-presentation as both CD56 lo CD16 + and CD-56 hi CD16 Ϫ NK cell subsets had a similar level of incorporated BrdU during treatment ( Fig. 5 A ) . Although one cannot distinguish between CD16 + NK cells that have incorporated BrdU and BrdU + cells that have up-regulated CD16, it is most likely that the latter accounts for most of the BrdU + CD16 + NK cells as CD56 lo CD16 + NK cells are refractory to IL-15 stimulation in vitro ( 25, 26 ) , especially when compared with CD56 hi CD16 Ϫ NK cells ( Fig. 1 E ) . To test this hypothesis, we sorted and transferred either highly purifi ed CD56 hi CD16 Ϫ KIRs Ϫ or CD56 lo CD16 + KIRs Ϫ NK cells from fetal spleen into BALB/c Rag2 Ϫ / Ϫ ␥ c Ϫ / Ϫ in the presence or absence of RLI treatment. Although we were unable to recover the donor cells in mice receiving PBS alone, clear populations of donor cells were recovered from RLI-treated mice 7 d after transfer ( Fig. 5 B ) . Consistent with our hypothesis, trans-presented IL-15 induced the diff erentiation of CD-56 hi CD16 Ϫ NK cells, with between 34 and 40% of recovered NK cells becoming CD16 + ( Fig. 5 B ) . In addition a fraction of the CD16 + NK cells also now expressed KIRs. Similarly, whereas CD56 lo CD16 + NK cells retained this phenotype in the presence of RLI after transfer, expression of KIRs were acquired by a fraction of these CD56 lo CD16 + NK cells that lacked KIR expression before transfer ( Fig. 5 B ) . The absence of NK cells in non-RLI treated recipients clearly shows that the available mouse IL-15 is inadequate to support human NK cell survival and highlights the importance of a source of hIL-15 in HIS mice in promoting NK cell diff erentiation.
Binding of IL-15 to NK cells ultimately activates signaling pathways stemming from STAT5 phosphorylation, such as activation of NF-B, induction of cyclin D, down-regulation of proapoptotic proteins, and up-regulation of Bcl-2 family members and cytolytic granules ( 18, 24, 27 ) . Although it is clear how these signaling events promote cell division, survival, and eff ector functions, it is not known how these pathways regulate acquisition of KIRs. Coordination between granzyme/perforin induction and KIR expression would be one means to limit NK cell activity during diff erentiation, and whereas most NK cells express other inhibitory receptors for MHC-I (CD94/NKG2A and LILR) throughout development, it appears acquisition of KIRs is a late event and likely unique NK cell development and suggests that trans-presented IL-15 promotes this diff erentiation. CD16 expression is associated with human NK cell diff erentiation and increased cyto toxicity by means of increased intracellular eff ector granules and the ability to perform antibody-dependent cell cytotoxicity. IL-15 itself is known to enhance NK cell cytotoxicity via up-regulating eff ector molecules, such as IFN-␥ , perforin, and granzymes ( 24 ) . Strikingly, among the enhanced CD16 + population after IL-15 trans-presentation treatment, the percentage of NK cells expressing KIRs was also signifi cantly elevated, resulting in a large increase in the KIR + NK cell pool, an eff ect that is also more prominent with RLI ( Fig. 4 A ) . The fraction of KIR + NK cells after exogenous IL-15 trans-presentation was typically 
observe accumulation of CD16 + KIR + NK cells in HIS mice with HSCs ectopically expressing Bcl-xL suggests that NK cell survival alone is not suffi cient to promote diff erentiation and a source of hIL-15 is essential for this process.
Factors regulating KIR expression on developing NK cells in vivo are undefi ned. Our study provides the fi rst evidence that trans-presented IL-15 induces KIR expression on CD-56 lo CD16 + NK cells in vivo and suggests that KIRs are expressed after CD16 and that acquisition of KIRs represents a further step in NK cell diff erentiation. Interestingly, expression of human self -MHC-I on a fraction of the hematopoietic cells in HIS mice appears suffi cient in generating phenotypically mature KIR + NK cells. Our fi ndings suggest use of hIL-15R agonists in vivo may augment human NK cell diff erentiation, and subsequently functionality, and could benefi t patients with compared with other forms of MHC-I -mediated inhibition. Collectively, these data provide the fi rst in vivo demonstration that trans-presented IL-15 is essential for NK cell survival and subsequent diff erentiation and that KIR expression on mature NK cells is dynamically regulated by IL-15 signaling.
Concluding remarks
Mouse studies show that IL-15 functions as a membranebound cytokine that can only be present at the cell surface and support NK cell development when bound to IL-15R ␣ on the same cell ( 9, 10 ) . The clear eff ect of hIL-15R ␣ to enhance hIL-15 activity in vivo suggests this is also likely in man. Our fi ndings using a novel HIS mouse approach demonstrates that hIL-15 trans-presentation is necessary to promote human NK cell development and diff erentiation in vivo. The failure to In vivo treatments. HIS mice were injected i.p. with 100 μ l of hIL-15 (2.5 μ g) and hIL-15R ␣ -Fc (7.5 μ g) + hIL-15 (2.5 μ g) both from R & D Systems, 2.5 μ g RLI ( 20 ) , or PBS alone, commencing at a minimum of 6 wk after reconstitution. 100 μ l of 10 mg/ml of BrdU from BrdU fl ow kit (BD) was injected i.p. daily 2 d before sacrifi cing mice. For NK cell transfer assays, 3 × 10 4 CD56 hi CD16 Ϫ KIRs Ϫ or 2 × 10 5 CD56 lo CD16 + KIRs Ϫ NK cells were sorted from human CD45 + CD3 Ϫ fetal splenocytes (15-wk gestation) and transferred intrheaptically into 1-wk-old sublethally irradiated BALB/c Rag2 Ϫ / Ϫ ␥ c Ϫ / Ϫ mice. A cocktail of KIR antibodies recognizing KIR-2DL2/3/1/-2DS1/2/4/-3DL1/S1 was used. Recipients were then treated i.p. with PBS or 2. , Bcl-xL (7B2.5), and CD159a (NKG2A; Z199) from Beckman Coulter; granzyme B (GB11) from Invitrogen; and CD11b (ICRF44), CD25 (BC96), CD116 (4H1), CD83 (HB15e), anti -mouse NK1.1, CD11b, CD11c, F480, and DX5 from eBioscience. Intracellular staining was performed after fi xation and permeabilization of the cellular suspensions using Perm/Wash and Cytofi x/Cytoperm reagents from BD according to the manufacturer ' s instruction. For BrdU detection, cells were incubated for 1 h at 37 ° C with 30 μ g DNase from BrdU fl ow kits (BD). All washings and reagent dilutions were done with PBS containing 2% FCS. All acquisitions were performed using LSRII, Canto 1, or Canto 2 cytometers, cell sorting was performed using FACSAria, and all machines were interfaced to the FACSDiva software (BD).
Cell preparation. Human fetal liver was obtained from elective abortions, with gestational age ranging from 14 to 20 wk. Experiments using human fetal liver cells were approved by the Medical and Ethical Committees at the Institut Pasteur and AMC-UvA and performed in full compliance with French law. Single-cell suspensions of fetal material were achieved by mechanical disruption using a Stomacher Biomaster laboratory system (Seward). Magnetic enrichment of CD34 + cells ( > 98% pure) was performed by using the CD34 Progenitor Cell Isolation kit (Miltenyi Biotech, Auburn, CA), after preparation of single-cell suspension and isolation of mononuclear cells by density gradient centrifugation over Ficoll-Hypaque (Nycomed Pharma). Cell suspensions were prepared in RPMI medium with 2% FCS. Single-cell suspensions of mouse organs were prepared as previously described ( 17 ) .
In vitro assays. Human NK cells were purifi ed from donor blood buff y coat prepared by density gradient centrifugation over Ficoll-Hypaque (Nycomed Pharma) using anti-CD56 magnetic beads (Miltenyi Biotech). C57BL/6 splenic NK cells were purifi ed by anti-DX5 magnetic beads (Miltenyi Biotech). Purifi ed cells were loaded with 5 μ M CFSE (Invitrogen) and cultured at 2 × 10 5 cells/ml in RPMI with 10% FCS and 10 ng/ml rhIL-15 (rhIL-15; R & D Systems) or 30 ng/ml rmIL-15 (Peprotech) for 3 or 5 d. Alternatively, 10 4 CD56 + NK cells purifi ed from human peripheral blood were labeled with CFSE and cultured for 72 h in combinations of human or mouse IL-15 that had been preincubated with human or mouse IL-15R ␣ -Fc for 1 h at 4 ° C. The fi nal concentration of IL-15 and IL-15R ␣ -Fc were underrepresented populations of mature cytotoxic KIR + NK cells and improve NK cell -or CD8 T cell -based cancer immuno therapy strategies. The effi ciency of IL-15R agonists, particularly RLI, in augmenting human NK cell development in HIS mice will enable us to more readily dissect the role of IL-15-dependent lymphocytes (NK cell, memory CD8 T cell, NK T cell, and ␥ / ␦ T cell) responses to human pathogens and disease in vivo. Given obvious cross talk between innate and adaptive immune cells, having robust reconstitution of IL-15dependent cells in vivo improves the accuracy and application of HIS mice for studying human immune responses. Collectively, our results defi ne an essential role for IL-15 in human NK cell development in vivo and demonstrate the effi cacy of IL-15 -IL-15R ␣ complexes in promoting human NK cell homeostasis, suggesting hIL-15 is likely bound and trans-presented by IL-15R ␣ -expressing cells in man.
MATERIALS AND METHODS
Mice. C57BL/6 mice were purchased from Harlan. Rag2 Ϫ / Ϫ ␥ c Ϫ / Ϫ mice were backcrossed onto the BALB/c background and BALB/c Rag2 Ϫ / Ϫ ␥ c Ϫ / Ϫ mice on a Nude background were bred and maintained in isolators with autoclaved food and water under a protocol approved by the AMC-UVA. Mice with a HIS were generated as previously described ( 15, 16 ) . In brief, newborn (3 -5-d-old) Rag2 Ϫ / Ϫ ␥ c Ϫ / Ϫ mice received sublethal (3.3 Gy) total body irradiation from a Cs source, and were injected intrahepatically with 10 5 sorted CD34 + CD38 Ϫ or 5 × 10 5 CD34 + human fetal liver cells. All manipulations of HIS mice were performed under laminar fl ow. Mouse experiments were approved by an institutional committee at the Institut Pasteur and validated by the French Ministry of Agriculture. Retroviral Bcl-xL expression. Human fetal liver cells were prepared and modifi ed by retroviral transduction as follows. The sorted CD34 + CD38 Ϫ fetal liver cells were cultured overnight in IMDM (Invitrogen) supplemented with Yssel ' s medium, 5% normal human serum, 20 ng/ml human stem cell factor, 20 ng/ml human thrombopoietin, and 20 ng/ml human IL-7 (Pepro-Tech). The next day, cells were incubated for 6 -8 h with control LZRS IRES-GFP or LZRS Bcl-xL-IRES-GFP virus supernatant in fi bronectincoated plates (30 μ g/ml; Takara Biomedicals). The cell bulk was then inoculated intrahepatically to the newborn recipients. The cDNA sequence encoding Bcl-xL, initially provided by the laboratory of J.G. Collard (The Netherlands Cancer Institute, Amsterdam, Netherlands) was inserted into the multiple cloning sites of LZRS vector upstream of an internal ribosomal entry site and enhanced GFP ( 28 ) . Control vectors were empty LZRS IRES. Retroviral supernatants were produced as previously described ( 29 ) using the 293T-based Phoenix packaging cell line ( 30 ) .
